Halozyme Therapeutics Inc (HALO)

Operating return on assets (Operating ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	551,475	477,009	402,091	379,314	337,574	311,048	306,061	245,663	267,531	249,556	241,850	300,837	275,902	296,992	261,705	198,213	144,255	34,569	-30,267	-73,799
Total assets	US$ in thousands	2,063,480	2,118,030	1,969,450	1,841,530	1,733,270	1,892,660	1,810,440	1,699,450	1,841,510	1,864,540	1,781,390	1,162,250	1,104,430	1,185,420	1,025,860	966,582	579,924	524,029	526,997	492,353
Operating ROA		26.73%	22.52%	20.42%	20.60%	19.48%	16.43%	16.91%	14.46%	14.53%	13.38%	13.58%	25.88%	24.98%	25.05%	25.51%	20.51%	24.87%	6.60%	-5.74%	-14.99%

December 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $551,475K ÷ $2,063,480K
= 26.73%

Operating ROA is a key financial ratio that measures a company's efficiency in generating operating profit from its assets. Halozyme Therapeutics Inc's operating ROA has shown a fluctuating trend over the past few years.

The company's operating ROA started in negative territory at the beginning of 2020 but gradually improved throughout the year, turning positive by the end of December 2020. Subsequently, there was a further increase in operating ROA reaching a peak of 26.73% by the end of December 2024.

The overall trend indicates that Halozyme Therapeutics Inc has been able to effectively generate higher operating profits relative to its assets, with an increasing trend in recent periods. This improvement suggests that the company has been able to enhance its operational efficiency and profitability over the years, which can be a positive indicator of its financial health and performance.